Methotrexate and biological therapy are not associated with fatty liver in rheumatoid arthritis—a cross-sectional study
- 24 September 2025
- journal article
- research article
- Published by Springer Nature in Rheumatology International
- Vol. 45 (10) , 1-13
Abstract
The prevalence of non-alcoholic fatty liver disease (NAFLD) in patients with rheumatoid arthritis (RA) is approximately 30%. The relationship between conventional synthetic and biologic disease-modifying antirheumatic drugs (csMDARDs and bDMARDs) and NAFLD is complex and requires careful consideration in clinical practice. This study evaluates the impact of various treatment regimens and analyzes the relationship between NAFLD, defined by a controlled attenuation parameter (CAP) threshold of 275 dB/m, and liver fibrosis (liver stiffness measurement > 8 kPa) and clinical parameters in 170 RA patients. Treatment groups were categorized based on methotrexate (MTX) use (“YES” and “NO”) and the use of biologic agents, including tumor necrosis factor inhibitors (TNFi), interleukin-6 (IL-6) inhibitors, as well as non-treatment groups. The prevalence of NAFLD in RA patients was found to be 36%, primarily attributed to components of metabolic syndrome and obesity including body-mass index (BMI), waist (WC) and hip circumference (HC), alanine aminotransferase (ALT), aspartate aminotransferase (AST) (all p < .001) triglycerides (p = .049). No significant differences in NAFLD prevalence were observed between treatment groups or between MTX treatment groups (cumulative doses < 3 g and > 3 g; p = 1.0). Furthermore, TNFi treatment duration did not show a significant correlation with NAFLD (Spearman’s rho = 0.024, p = .897) or with fibrosis severity (Spearman’s rho = 0.087, p = .640). In contrast, the duration of IL-6 inhibitor treatment demonstrated a significant negative correlation with NAFLD (Pearson’s r=-0,41, p = .029). Methotrexate does not appear to influence NAFLD or fibrosis in RA patients. In contrast, long-term use of IL-6 receptor inhibitors may contribute to a reduction in NAFLD.Keywords
This publication has 46 references indexed in Scilit:
- The Role of Tumor Necrosis Factor-Alpha in the Pathogenesis and Treatment of Nonalcoholic Fatty Liver DiseaseCurrent Obesity Reports, 2023
- Treatment of rheumatoid arthritis with conventional, targeted and biological disease-modifying antirheumatic drugs in the setting of liver injury and non-alcoholic fatty liver diseaseRheumatology International, 2022
- Mechanisms and disease consequences of nonalcoholic fatty liver diseaseCell, 2021
- Methotrexate does not increase the risk of liver fibrosis in patients with rheumatoid arthritis: assessment by ultrasound elastography (ARFI-MetRA study)Rheumatology International, 2021
- Metabolic syndrome in rheumatoid arthritis patients: Relationship among its clinical componentsJournal of Clinical Laboratory Analysis, 2020
- Methotrexate use does not increase the prevalence of hepatic steatosis: a real-world retrospective nested case-control studyClinical Rheumatology, 2020
- JAK inhibitors for the treatment of autoimmune and inflammatory diseasesAutoimmunity Reviews, 2019
- “Hepatic toxicity by methotrexate with weekly single doses associated with folic acid in rheumatoid and psoriatic arthritis. What is its real frequency?”Annals of Hepatology, 2019
- Impact of Obesity on Remission and Disease Activity in Rheumatoid Arthritis: A Systematic Review and Meta‐AnalysisArthritis Care & Research, 2016
- Understanding the role of cytokines in the pathogenesis of rheumatoid arthritisClinica Chimica Acta, 2016